exicuretx.com - Multiplikator Forward P/S XCUR
Exicure, Inc. (XCUR) faces a critical funding shortage and the threat of delisting in the absence of new investments. On GURU.Markets, the projected market cap-to-revenue ratio, where 70.90 represents the current metric level, demonstrates the potential of RNA-based oncology drugs. The company is currently urgently restructuring its R&D pipeline, developing targeted SNA products to overcome the stagnation in clinical trials.
Ringkesan rincian data analitis exicuretx.com (XCUR)
- rega pasar lan target rega analis:
- rincian nilai pasar emiten:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal Exicure, Inc.|XCUR - Rasio utang jangka dawa marang ekuitas|Rasio utang jangka cendhak marang ekuitas Exicure|XCUR - Gunggung utang perusahaan|Rasio utang marang kapitalisasi buku Exicure, Inc.|XCUR - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Exicure|Likuiditas cepet exicuretx.com
- indikator pendapatan resik lan kelipatan nilai:
XCUR - Bathi perusahaan|Proyeksi bathi mangsa ngarep Exicure, Inc.|XCUR - Pangali P/E|Pangali Forward P/E Exicure|XCUR - Rega marang bathi kanthi panyesuaian wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Exicure, Inc.|XCUR - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Exicure|XCUR - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi EPS kuartalan exicuretx.com|XCUR - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi saben saham kanggo taun ngarep Exicure, Inc.
- indikator volume dodolan lan pendapatan:
Analisis fundamental perusahaan:XCUR (Exicure Corp)
Downsizing the workforce to a compact scientific core and transitioning to external contracts minimize costs for Exicure, Inc. (XCUR), focusing capital on development. The ratio of current market capitalization to projected revenue allows for an assessment of market expectations for future sales; therefore, analyzing the company's projected P/S chart helps investors recognize asset overvaluation in a timely manner and avoid buying at local peaks.
Pesaing wigati
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|QGEN: Kapitalisasi marang prakiraan pendapatan|Ionis Pharma - Multiplikator Forward P/S|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA (Avidity Biosciences) - Multiplikator forward rega marang pendapatan|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan WGS|Kapitalisasi marang prakiraan pendapatan RARE (Ultragenyx Pharmaceutical Inc.)|Multiplikator Forward P/S BEAM|Multiplikator forward rega marang pendapatan Sarepta Corp SRPT|Twist Bioscience - Multiplikator forward rega marang pendapatan|Multiplikator Forward P/S 10xgenomics.com TXG|NTLA - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan STOK (Stoke Therapeutics Inc)|BLFS: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan WVE|Rasio rega marang prakiraan pendapatan Maze Therapeutics Inc|Kapitalisasi marang prakiraan pendapatan SION (sionnatx.com)|Multiplikator Forward P/S PRME|Multiplikator Forward P/S Taysha Gene Therapies Inc (TSHA)|Multiplikator Forward P/S QURE (uniQure Corp)|MeiraGTx Corp (MGTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|RGNX: Multiplikator forward rega marang pendapatan|SLDB (solidbio.com) - Kapitalisasi marang prakiraan pendapatan|OCGN: Multiplikator Forward P/S|PACB - Rasio kapitalisasi marang dodolan sing dikarepake|BNTC (Benitec) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Design Corp (DSGN)|Multiplikator forward rega marang pendapatan RCKT (Rocket Pharmaceuticals)|Multiplikator Forward P/S 4dmoleculartherapeutics.com (FDMT)|Rasio rega marang prakiraan pendapatan Lexeo Therapeutics, Inc. LXEO|Rega forward marang dodolan KRRO|Editas - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Silence Therapeutics Corp|PRQR (proqr.com) - Multiplikator forward rega marang pendapatan|Codexis - Rega forward marang dodolan|SGMO (Sangamo Therapeutics, Inc.) - Multiplikator Forward P/S|Nautilus Biotechnology Inc (NAUT) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Metagenomi, Inc (MGX)|Precision BioSciences Inc. - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S GBIO (Generation Bio)|BOLD - Multiplikator forward rega marang pendapatan|IMNN: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Phio Pharmaceuticals PHIO|MBIO (mustangbio.com) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan RNAZ|BNGO (Bionano Genomics Inc.) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan adnas.com (APDN)|Multiplikator forward rega marang pendapatan BLUE (bluebird bio)|Multiplikator Forward P/S immunoprecise.com (IPA)|Rasio rega marang prakiraan pendapatan Omega OMGA|Rega forward marang dodolan OMIC|Regulus Therapeutics - Multiplikator Forward P/S|SYRS (syros.com) - Kapitalisasi marang prakiraan pendapatan|Telesis Bio (TBIO) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TCON|UBX (Unity Bio) - Multiplikator Forward P/S
